UNSPSC 51294907: Tienopramine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36L0QUK8SY. European Medicines Agency schedules Tienopramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11034MIG. Tienopramine generally arises in the molecular formula C17H20N2S.

UNSPSC 51294907 Tienopramine is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though the recent opportunity record shows a mismatch: Seminole County, Florida solicited naloxone and drug deactivation systems under this code, which does not align with tienopramine's nominal scope. The single recent opportunity on record reflects a county health department's purchase of emergency response pharmaceuticals and related medical systems rather than tienopramine specifically. State and local governments use codes in this family to procure controlled pharmaceuticals, medical countermeasures, and allied health supplies through standard competitive bidding.

Seminole County, Florida is the only issuing body with a recent posted opportunity under this code. The county issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023. The contract terms include a two-year initial award period with a one-year renewal option, fixed-fee pricing, E-Verify compliance, standard insurance coverage (workers' compensation, commercial general liability, and professional liability), and a three-month probationary termination clause. Potential FEMA funding introduces additional federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The code shows limited recent state and local procurement activity; firms tracking this category should note the divergence between the code's nominal scope and the naloxone-focused opportunity currently on record.